A tablet described as an NAD product may contain NAD itself, a precursor such as NR or NMN, or a combination. The front label is not enough to identify which evidence applies. Start with the exact ingredient and formulation tested in the cited study.

A randomized trial of oral NR in middle-aged and older adults reported effects on NAD metabolism. That study supports a specific biochemical observation for NR under its study conditions; it does not establish that all products marketed around NAD have the same effect. NR crossover trial in healthy middle aged and older adults

A higher biomarker is not the whole outcome

Researchers may measure blood metabolites, tissue responses, symptoms or physical function. These measurements answer different questions. A change in a biochemical marker can justify further investigation without demonstrating an improvement that a person would notice or a reduction in future disease.

A later randomized study examined NR in older adults with subjective cognitive decline or mild cognitive impairment. After eight weeks, it did not demonstrate cognitive improvement: neither the primary conventional cognitive assessment nor digital cognitive measures showed a significant between-group benefit. A reported reduction in the plasma pTau217 biomarker does not overturn the negative cognitive finding or establish a clinical benefit. The small, short study also cannot determine whether longer treatment changes disease progression. NR cognition trial full report

Formulation claims need direct support

Terms such as enhanced absorption or advanced delivery should be linked to suitable measurements of the actual product. Evidence for an ingredient does not automatically establish the performance of a new tablet technology or mixture. A different formulation can introduce new uncertainty even when the ingredient list looks familiar.

AXON's conclusion is that NAD-related tablet research should be organized by molecule, product and measured outcome. The cited evidence does not establish human lifespan extension or universal benefit. This article recommends no supplement and gives no dosing instructions. A clinician should assess individual health questions, while any commercial claim requires scientific and regulatory review.